TCF4, a master regulator of pDC differentiation, which is known to mutually regulate RUNX2, was recently identified as a critical transcription factor for the survival of BPDCN cells by RNAi screening12. Here, TCF4 is linked to CD4+/CD56+ hematodermic neoplasm.